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Upregulation of TGF-b1 Expression May Be
Necessary but Is Not Sufficient for Excessive Scarring
Anelisa B. Campaner1,2, Lydia M. Ferreira2, Alfredo Gragnani2, Jan M. Bruder1, Jennifer L. Cusick3 and
Jeffrey R. Morgan1
Transforming growth factor beta 1 (TGF-b1) upregulation has been implicated in hypertrophic scars and keloids,
but it is unclear if it is the cause or an effect of excessive scar formation. In this study, we overexpressed TGF-b1
in fibroblasts and characterized its role. Normal human dermal fibroblasts were genetically modified to
overexpress TGF-b1 as the wild-type latent molecule or as a mutant constitutively active molecule. TGF-b1
secretion was measured, as were the effects of TGF-b1 upregulation on cell proliferation, expression of smooth
muscle cell alpha actin (SMC a-actin) and ability to contract collagen lattices. Fibroblasts were implanted
intradermally into athymic mice and tissue formation was analyzed over time by histology and immunostaining.
Gene-modified fibroblasts secreted B20 times the TGF-b1 released by control cells, but only cells expressing
mutant TGF-b1 secreted it in the active form. Fibroblasts expressing the active TGF-b1 gene had increased levels
of SMC a-actin and enhanced ability to contract a collagen lattice. After intradermal injection into athymic mice,
only fibroblasts expressing active TGF-b1 formed ‘‘keloid-like’’ nodules containing collagen, which persisted
longer than implants of the other cell types. We conclude that upregulation of TGF-b1 by fibroblasts may be
necessary, but is not sufficient for excessive scarring. Needed are other signals to activate TGF-b1 and prolong
cell persistence.
Journal of Investigative Dermatology (2006) 126, 1168–1176. doi:10.1038/sj.jid.5700200; published online 23 February 2006
INTRODUCTION
Fibrosis, the abnormal and excessive deposition of fibrous
tissue, occurs in many diseases including liver cirrhosis,
pulmonary fibrosis, scleroderma, and wound healing of the
skin after trauma or surgery (O’kane and Ferguson, 1997).
Fibrosis in the skin can lead to the formation of abnormal
scars, hypertrophic scars or keloids, which can cause
significant problems in tissue growth, function, and move-
ment. The problem is particularly acute following large deep
second- and third-degree burns.
Keloids and hypertrophic scars are both benign prolifera-
tions of the dermis. A keloid is a dermal lesion that spreads
beyond the margins of the original wound, continues to grow
over time, does not regress spontaneously, and commonly
recurs following treatment. By contrast, a hypertrophic scar is
a raised scar that remains within the boundaries of the
original lesion, often regresses spontaneously several months
after the initial injury and rarely recurs after treatment.
Clinically, treatment is challenging and despite a wide array
of options (corticoids, radiation, lasers, surgery, and inter-
feron), recurrence of keloids after treatment is frequent,
varying from 45 to 100% (Niessen et al., 1999).
There is little understanding of the molecular mechanisms
leading to the formation of keloids or hypertrophic scars, nor
is there an adequate animal model for their study, as they
occur only in humans. A leading theory proposes that
upregulation of transforming growth factor beta 1 (TGF-b1)
expression drives excessive cell proliferation and matrix
synthesis (Border and Noble, 1994). TGF-b1 and its family
members b2 and b3 are one of the only few cytokines known
to stimulate collagen synthesis, and several studies have
shown that it is upregulated in hypertrophic scars and keloids
(Ghahary et al., 1993; Younai et al., 1994; Tredget et al.,
1998; Lee et al., 1999; Wang et al., 2000; Hanasono et al.,
2003). It is also well known that TGF-b1 is an autocrine factor
produced by fibroblasts that is capable of upregulating its
own synthesis (Van Obberghen-Schilling et al., 1988;
Tomasek et al., 2002).
However, synthesis and activation of TGF-b1 and its
family members b2 and b3 is a complex process. TGF-b1 is
synthesized in a latent form as part of a large precursor
molecule. TGF-b1 is proteolytically cleaved from the pre-
cursor as it is secreted, but remains noncovalently bound to
the latency-associated peptide. Much of the TGF-b1–latency-
associated peptide complex is stored in the extracellular
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matrix because of the fact that latency-associated peptide is
covalently bound to another protein, the latent TGF-b1-
binding protein. Most importantly, TGF-b1 in this complex is
inactive. Once released from this complex, TGF-b1 is active
and can bind/signal its cellular receptor. TGF-b1 is liberated
by extremes of pH and heat in vitro as well as by proteases
such as furin and plasmin (Gleizes et al., 1997; Khalil, 1999).
Other proteins, such as thrombospondin, have been im-
plicated in the release of TGF-b1 in vivo, although other
mechanisms may be operable (Murphy-Ullrich and Poczatek,
2000).
Although upregulation of TGF-b1 expression has been
implicated in the formation of hypertrophic scars and keloids,
it is unclear if it is the cause or merely an effect of the
formation of these scars. Moreover, activation of TGF-b1 is
probably a critical regulatory step in this process. In this
study, we used genetic modification to directly test the
hypothesis that TGF-b1 upregulation contributes to fibrosis in
the skin. We genetically modified normal human dermal
fibroblasts to overexpress TGF-b1 in one of two forms; the
wild-type latent molecule or a mutant form that is constitu-
tively active. The modified cells secreted high levels of TGF-
b1, but only cells transfected with the mutant gene secreted it
in the active form. These cells also had increased levels of
smooth muscle cell (SMC) a-actin and an enhanced ability to
contract a collagen lattice. When implanted intradermally
into athymic mice, only cells expressing the active mutant
TGF-b1 formed nodules and these structures persisted longer
than implants of control cells or cells overexpressing latent
TGF-b1. The role of TGF-b1 in hypertrophic scars and keloids
are discussed in light of these results.
RESULTS
Fibroblasts transfected with the mutant gene produce high
levels of active TGF-b1
Diploid human fibroblasts were genetically modified with a
recombinant retrovirus encoding either wild-type (latent)
TGF-b1, which is secreted as a latent molecule and requires
activation, or a mutant form of TGF-b1 (cysteines 223 and
225 were converted to serines), which is secreted as an active
molecule and does not require activation (Figure S1). To
determine how much TGF-b1 was secreted, control and
gene-modified fibroblasts were grown to confluence and
aliquots of the medium harvested at different time points, and
levels of TGF-b1 measured by ELISA (Figure 1). To distinguish
between TGF-b1 secreted in the latent form versus the active
form, samples were either activated by acidification or not
activated before ELISA. In samples that were activated, cells
expressing the wild-type latent form of TGF-b1 accumulated
18 times more TGF-b1 than control unmodified cells after
48 hours, and cells expressing the mutant active form of TGF-
b1 accumulated 21 times the amount (Figure 1a). The rates of
total TGF-b1 production (latent plus active) were 2.6 ng/
106 cells/48 h for control cells (1.1 ng/ml at 24 hours),
48.5 ng/106 cells/48 h for latent cells (17.9 ng/ml at 24 hours),
and 56.7 ng/106 cells/48 h for mutant active cells (8.3 ng/ml at
24 hours). These ELISA data of activated samples measure the
level of TGF-b1 in the latent as well as the active form. To
determine how much TGF-b1 was secreted in the active
form, the same samples were assayed without activation
before ELISA (Figure 1b). Cells expressing latent TGF-b1
accumulated the same amount of active TGF-b1 as control
cells (0.22 ng/106 cells/48 h) (0.084 ng/ml at 24 hours), but the
rate of active TGF-b1 production by cells expressing the
mutant gene was 300 times higher (67.2 ng/106 cells/48 h)
(4.4 ng/ml at 24 hours).
Proliferation is decreased in fibroblasts expressing
active TGF-b1
To determine whether TGF-b1 expression altered fibroblast
proliferation, control and modified cells were plated into six-
well plates, trypsinized and counted every day (Figure 2). For
the first 48 hours, the proliferation of all cells was compar-
able. After 2 days, control and cells expressing latent TGF-b1
proliferated at comparable rates and reached confluence in 5
days. In contrast, cells expressing active TGF-b1 proliferated
slower, and required an additional 48 hours to reach
confluence (Figure 2a). The doubling time for control cells
and cells expressing latent TGF-b1 wasB20–24 hours versus
B48 hours for cells expressing active TGF-b1. A similar result
was obtained when performing the growth curve with WST-1
(Figure 2b). After reaching confluence, cells were followed
for up to 21 days to evaluate cell morphology (Figure 2c). In
the first few days, the cell morphology for all groups was
comparable. By the end of 21 days, the slower growing cells
expressing active TGF-b1 had about half as many cells
(60104 cells/well) as control cells or cells expressing latent
TGF-b1 (111 104). One week after reaching confluence,
cells expressing active TGF-b1 started to form aggregates and
clusters that grew larger with time, whereas control cells and
cells expressing latent TGF-b1 did not.
Levels of SMC a-actin are increased in fibroblasts expressing
active TGF-b1
To determine whether levels of SMC a-actin were altered,
control and modified fibroblasts were grown to confluence
and incubated in medium containing 1% serum for 48 hours.
Cells were lysed with a buffer containing 1% SDS, and equal
amounts of total protein were fractionated by SDS-PAGE,
transferred to nitrocellulose membranes and probed by
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Figure 1. Fibroblasts expressing the mutant gene secrete high levels of active
TGF-b1. Control unmodified cells and gene-modified cells expressing either
latent TGF-b1 or mutant active TGF-b1 were grown to confluence and
aliquots of the medium harvested at various times and measured for levels of
TGF-b1 by ELISA. The ELISA cannot measure TGF-b1 in the latent form. (a)
Samples were acidified to release latent TGF-b1 before ELISA or (b) samples
were not acidified before ELISA.
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Western blotting. Compared to controls and cells expressing
latent TGF-b1, cells expressing active TGF-b1 had increased
levels of SMC a-actin (Figure 3a). The same membrane was
stripped and probed for b-actin, showing that differences in
SMC a-actin levels were not due to differences in loading, as
the levels of b-actin were comparable. To estimate the
increase in SMC a-actin levels, varying amounts of total
protein (5, 10, 15, and 20 mg) were loaded and probed by
Western blotting. These data show that SMC a-actin levels
were 2–3-fold higher in cells expressing active TGF-b1 versus
control cells and cells expressing latent TGF-b1 (Figure 3b).
Contraction of collagen lattices is enhanced by gene-modified
fibroblasts
To evaluate the ability of fibroblasts to contract collagen
lattices, control and modified cells were cast into floating
collagen lattices and monitored contraction over time
(Figure 4). Collagen lattices were rapidly contracted by
transfected cells from a starting diameter of 3.3 cm to less
than 2 cm in the first 24 hours. Lattices with cells expressing
latent TGF-b1 and active TGF-b1 contracted from 3.3 to
1.8 cm and 3.3 to 1.7 cm, respectively; whereas lattices with
control cells contracted from 3.3 to 2.7 cm in the first
24 hours. After 144 hours, contraction was greatest for cells
expressing active TGF-b1 (32% of its initial diameter)
compared to cells expressing latent TGF-b1 (58%) and
control cells (63%).
Cells expressing active TGF-b1 form nodules and persist longer
after implantation
To evaluate their growth and tissue organization in vivo,
control and gene-modified fibroblasts were implanted by
intradermal injection into athymic mice. Injection sites were
excised and pictures taken at each time point (Figure S2). At 3
days after injection, cells expressing latent or active TGF-b1
formed macroscopic nodules that were visible on the inner
side of the skin. Nodule formation by control cells was not
obvious. At 7, 10, and 14 days after injection, nodules were
only obvious for those cells expressing active TGF-b1 and
they had an enhanced macroscopic vascularization, mainly
at 7 days. Compared to their size at day 7, nodules formed by
cells expressing active TGF-b1 were somewhat smaller and
appeared to be contracted at days 10 and 14. At day 28 and
beyond, macroscopic nodules were not apparent for any of
the cell groups. These results were found in all animals tested
(eight animals/time point) with minimal variations in nodule
size and time of formation and disappearance.
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Figure 2. Fibroblasts expressing active TGF-b1 proliferate slower and form
cell clusters. (a) Control cells and gene-modified cells expressing either latent
TGF-b1 or active TGF-b1 (3 103 cell/cm2) were plated and at various time
points, the cells were trypsinized and counted. Cells were also plated in 96-
well dishes, incubated each day with the WST-1 reagent to assess viability
and cell number. (b) Absorbance was read in an ELISA plate reader. Error bars
represent standard deviation for three replicates (*Po0,001). (c) Photographs
of cells using phase contrast microscopy at day 2 (preconfluent) and day 21
(postconfluent) shows the formation of cell clusters by those cells expressing
active TGF-b1 (Bar¼ 100mm).
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Figure 3. Levels of SMC a-actin are increased in fibroblasts expressing active
TGF-b1. (a) Cell extracts (5 or 10mg of protein) from control cells (C), and
gene-modified cells expressing either latent TGF-b1 (L), or active TGF-b1 (A)
were separated by SDS-PAGE, transferred to a membrane and levels of SMA
a-actin measured by immunostaining. The membrane was stripped and
reprobed for levels of b-actin by immunostaining to ensure equal loading.
(b) Relative levels of SMA a-actin of the same cells were measured in the same
way by loading 5, 10, 15, and 20mg extract protein and immunostaining.
Image analysis of the signal from the different concentrations of extracts
showed that SMA a-actin levels were increased 2–3-fold in cells expressing
active TGF-b1.
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Figure 4. Time course of contraction of fibroblast-populated collagen
lattices. (a) Control cells and gene-modified cells expressing either latent
TGF-b1 or active TGF-b1 were cast in floating collagen gels and the rate of
contraction determined by measuring lattice diameter. Error bars represent the
standard deviation of six replicates (*Po0.001). Results were significant at
each time point throughout the curves. (b) Photograph of the lattices after
144 hours of contraction.
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To examine their organization, the sites of injection were
evaluated by histology (hematoxilin & eosin) (Figure 5). At
days 3 and 7, the injection sites for modified cells as well as
control cells could be identified even though the control cells
did not form a visible nodule. At these early time points, the
injection sites of all groups had areas of high cell density that
were approximately the same size, except for cells expressing
active TGF-b1 that were bigger, and with little tissue
organization. Control cells and cells expressing latent TGF-
b1 tended to be more spread out from the injection site,
whereas cells expressing active TGF-b1 were collected in a
more sphere-like formation. Compared to control cells, blood
vessels seemed more abundant for cells expressing active
TGF-b1, followed by cells expressing latent TGF-b1. From
day 10 onward, it was difficult to conclusively identify the
control cells and those expressing latent TGF-b1, whereas
cells expressing active TGF-b1 formed distinct nodules, most
obvious at day 14. At this point, cell density of the nodules
was lower than sites at early times after injection and cell
density was not homogenous. Nodules had the highest
density of cells at the periphery and a decrease in cell
density toward the center. The entire nodule also appeared to
be encapsulated by mouse connective tissue. Blood vessels
were located predominately around the periphery of the
nodule. Nodules formed by cells expressing active TGF-b1
persisted for as long as day 28 but decreased significantly in
size.
To definitively identify which cells were human fibro-
blasts, cryosections were immunostained with a monoclonal
antibody that recognizes human vimentin and does not
crossreact with murine vimentin (Figure 6). Immunostaining
confirmed, that at all time points for all groups where a
nodule was macroscopically visible, it contained human
fibroblasts. Immunostaining also revealed human fibroblasts,
even if no nodule was visible. Control cells and cells
expressing latent TGF-b1 were detected 28 days after
injection. These cells were fewer in number and were more
integrated into the mouse tissue than cells expressing active
TGF-b1. Active TGF-b1-expressing cells were generally
confined to a nodule. Immunostaining also revealed that
the cells in the center and the periphery of the nodules were
human cells and clearly showed the boundary between
human cells and the mouse cells encapsulating the nodule.
When immunostained for collagen type 1, it was clear the
entire nodule contained abundant collagen, and the injected
human cells were producing collagen.
DISCUSSION
Keloids and hypertrophic scars are manifestations of an
abnormal process of tissue repair after trauma to the skin.
Options for treatment are limited by our lack of under-
standing of the molecular and cellular mechanisms governing
the formation of these scars. Moreover, as these lesions are
unique to humans, animal models for the development of
new therapeutic interventions are severely limited. Current
models, based on the implantation of human scar tissue
into athymic animals are cumbersome, limited by the
availability and variability of human tissue and are not
widely used, nor have they been used to pinpoint the
molecular and cellular events underlying these scars (Estrem
et al., 1987; Kischer et al., 1989; Waki et al., 1991; Hillmer
and MacLeod, 2002).
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Figure 5. Fibroblasts expressing active TGF-b1 form keloid-like tissue. Tissue
from injection sites were harvested at different times, fixed, paraffin-
embedded, sectioned (5 mm) and stained with hematoxilin & eosin. Little
organization of injected cells was evident for all groups at day 7. By day 14,
only fibroblasts expressing active TGF-b1 had formed nodular structures with
‘‘keloid-like’’ appearance. Note the high density of cells at the periphery
compared to the center and the nodule appears to be encapsulated by mouse
connective tissue. Nodules formed by fibroblasts expressing active TGF-b1
were evident at day 28, whereas the location of control fibroblasts or
fibroblasts expressing latent TGF-b1 were not obvious. Arrows mark sites of
obvious implants (Bar¼100 mm).
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Figure 6. Human fibroblasts and collagen type I are present in nodules
formed by cells expressing active TGF-b1. Cryosections (8mm) of injection
sites frozen in OCT were immunostained (a, b, d, e, f) for vimentin to reveal
human fibroblasts (c) or for collagen type I to highlight connective tissue and
collagen synthesis. (a, b) Nodules at day 14 formed by injected fibroblasts
expressing active TGF-b1 immunostained for human vimentin show the
variation in density of human cells in the nodule as well as the presence
of surrounding cells of the host. (c) Immunostaining of a serial section shows
that the nodule contains collagen type I. Immunostaining for vimentin of
injection sites at day 28 of (d) control fibroblasts, (e) fibroblasts expressing
latent TGF-b1, (f) and fibroblasts expressing active TGF-b1 show that human
cells are present for all groups at day 28. Control fibroblasts and fibroblasts
expressing latent TGF-b1 are integrated into the structures of the lower dermis
and panniculus carnosus, whereas fibroblasts expressing active TGF-b1
appear to be surrounding the remains of a nodule (inside circle) (Bars: a, d, e
and f¼ 200 mm; b and c¼100 mm).
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TGF-b1 induces collagen synthesis and has been shown to
be upregulated in scars and so a leading hypothesis is that
chronic overexpression of TGF-b1 or one of its fellow family
members b2 and b3 drives the formation of keloids and
hypertrophic scars. Yet, each TGF-b is secreted as a latent
molecule that requires activation and no study has estab-
lished a cause and effect relationship between TGF-b
overexpression and the formation of keloids or hypertrophic
scars. To investigate the role of TGF-b1 and its activation in
fibrosis of the skin, we genetically modified diploid human
skin fibroblasts to overexpress either wild-type TGF-b1,
which is secreted in a latent form, or mutant TGF-b1, which
is secreted in a constitutively active form. The mutations at
positions 223 and 225 (cysteines to serines) are located in the
latency-associated peptide portion of the gene and do not
alter the mature TGF-b1 polypeptide sequence; however,
they do disrupt latency-associated peptide folding and
prevent the formation of the latent complex with TGF-b1
(Brunner et al., 1989). Modified fibroblasts expressing the
wild-type gene secreted 18-fold more TGF-b1 than control
cells, but it was in the latent form and levels of active TGF-b1
released by these cells were comparable to controls. In
contrast, modified fibroblasts expressing the mutant gene
secreted 21-fold more TGF-b1 than control cells and it was in
the active form. These data show that human fibroblasts are
able to synthesize high levels of wild-type TGF-b1, but they
are unable to activate it. Moreover, these data show that
levels of secreted TGF-b1 (latent or active) are not limited by
the levels of latent TGF-b-binding protein gene expression
(Myazono et al., 1991; Saharinen et al., 1996). Others have
used a gene transfer approach to overexpress TGF-b1 in the
skin via transgenic animals or direct gene transfer (Sellheyer
et al., 1993; Benn et al., 1996).
Fibroblasts expressing active TGF-b1 proliferated slower
than either control cells or fibroblasts overexpressing latent
TGF-b1. Prior studies have shown that TGF-b1’s action on
fibroblast proliferation is complex. Proliferation of mink lung
fibroblasts is stimulated by low concentrations of TGF-b1
(5–10 ng), and inhibited by higher concentrations (Ghahary
et al., 2002), whereas cell proliferation of post confluent
cultures of human dermal fibroblasts is stimulated by TGF-b1
(Clark et al., 1997). In most proliferation studies, cells are
exposed to a bolus of active TGF-b1, whereas in our study,
cells are continually exposed to TGF-b1 (latent or active)
during the entire time they are cultured. In fact, when cells
were grown beyond confluence, only those cells expressing
active TGF-b1 formed distinct cell clusters or aggregates.
Based on observations from a prior study where fibroblasts
treated with TGF-b formed stratified cell layers interposed by
abundant extracellular matrix, our cell clusters could be sites
of excessive extracellular matrix deposition that stimulated
the local contraction of cells into aggregates (Clark et al.,
1997). This may be a dose-dependent phenomenon and so it
would be interesting to select for gene-modified cells
expressing different levels of TGF-b and determine its
influence on cell proliferation.
TGF-b1 is thought to induce the differentiation of
fibroblasts into myofibroblasts that reorganize extracellular
matrix and exert tensile forces on the provisional matrix of
healing wounds (Rudolph et al., 1992; Tomasek et al., 2002).
Compared to control cells and cells expressing latent TGF-b1,
fibroblasts expressing active TGF-b1 had a 2–3-fold increase
in the expression of SMC a-actin, a marker of myofibroblasts
that is upregulated by TGF-b1 (Desmoulie`re et al., 1993;
Serini and Gabbiani, 1996; Tomasek et al., 2002). Moreover,
contraction of collagen lattices was greatest for cells
expressing active TGF-b1 versus control cells. Interestingly,
contraction was also enhanced, but not as much, by cells
expressing latent TGF-b1, even though they did not express
higher levels of SMC a-actin. This is a consistent observation
and may be a limitation of the collagen gel contraction assay
possibly due to local effects (eg, pH) or the presence of other
factors in the serum or collagen preparation that may activate
TGF-b1.
When injected intradermally into athymic mice, the tissue
organization of fibroblasts expressing active TGF-b1 was
distinctly different than control cells or cells expressing latent
TGF-b1. These cells formed macroscopically evident nodules
that were well vascularized, appeared to contract with time
and persisted longer than controls or cells expressing latent
TGF-b1. At early times, cell density of control and both types
of modified cells was high and the cells had little if any
organization. Over time, cell density decreased for all groups
and cells expressing active TGF-b1 formed distinct nodules
encapsulated by mouse connective tissue. Within a nodule,
the density of human fibroblasts was greatest around the
periphery with few cells in the center that contained
abundant collagen. These features show similarities to the
histology of keloids and hypertrophic scars, although these
lesions are often confused and there is significant overlap in
their histology. Keloids are characterized by the presence of
whorls of thick, hyalinized collagen bundles or keloidal
collagen with mucinous ground substance and relatively few
fibroblasts; hypertrophic scars are characterized by nodular
structures with fine randomly organized collagen fibers
(Ehrlich et al., 1994; Lee et al., 2004). However, unlike
keloids that grow and hypertrophic scars that persist long
term, nodules formed by fibroblasts expressing active TGF-b1
decreased in size over time.
These data demonstrate that upregulation of TGF-b1 by
fibroblasts may be necessary but it is not sufficient for
the formation of keloids or hypertrophic scars. This conclu-
sion is supported by the observation that only those
fibroblasts expressing active TGF-b1, but not fibroblasts
overexpressing the wild-type latent TGF-b1 gene, formed
keloid-like nodules. Thus, simple upregulation of the
TGF-b1 gene, as seen in keloids or hypertrophic scars
(Ghahary et al., 1993; Younai et al., 1994; Tredget et al.,
1998; Lee et al., 1999; Wang et al., 2000; Hanasono
et al., 2003), is not enough. Present in the scar environment
must also be a signal that activates latent TGF-b1. Although
latent TGF-b1 can be activated by heat, extremes of pH,
chaotropic agents and detergents, the physiological relevance
of these is unknown. More relevant to scars is the fact
that latent TGF-b1 is activated by glycosidases, proteases
such as plasmin and cathepsin D and interaction with the
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adhesive protein thrombospondin-1 (Gleizes et al., 1997;
Khalil, 1999).
Even if TGF-b1 is activated, as was the case for our
fibroblasts expressing mutant active TGF-b1, the keloid-like
structures that these cells formed, decreased in size with time.
Parallel to this decrease in nodule size was a significant loss
of cells and a decrease in cell density at the injection site.
These data suggest that another signal must also be present
that either serves to maintain scar size, as is the case for
hypertrophic scars, or to expand scar size, as is the case for
keloids. We hypothesize that formation of keloids and
hypertrophic scars is a multistep process. Signals that serve
to maintain scar size might include apoptosis inhibition
(Desmoulie`re et al., 1995; Sayah et al., 1999; Teofoli et al.,
1999; Luo et al., 2001; Nakazono-Kusaba et al., 2004).
Signals that might stimulate the growth and expansion of a
scar might include platelet-derived growth factor (PDGF), a
factor well known for its ability to stimulate fibroblast
proliferation (Deul, 1987; Messadi et al., 1998), or other
factors like basic fibroblast growth factor and connective
tissue growth factor (Frazier et al., 1996; Takehara, 2000).
Moreover, several reports using a surgical model of scar
implantation into athymic rats have suggested that TGF-b2
and not TGF-b1 has a causative role in the formation of
proliferative scars (Polo et al., 1999; Smith et al., 1999; Wang
et al., 1999 and others have reported that a dysregulated
response to glucocorticoids may contribute to the pathology
(Russell et al., 1995).
Recombinant retroviruses can be used for the stepwise
genetic modification of human fibroblasts to express multiple
factors and the tissue organization of these cells can be
evaluated by intradermal injection as was done in this paper.
In this new approach to an animal model for studying the
steps to excessive scarring, we may be able to define tissue
structures that are intermediates to either a keloid or a
hypertrophic scar caused by the dysregulation of specific
growth factors and define the role of specific genes and
signaling pathways. The increased understanding of the
molecular and cellular events leading to the formation of
keloids and hypertrophic scars gained by this approach as
well as other approaches such as the biochemical character-
ization of fibroblasts from keloids/hypertrophic scars, the
implantation of human proliferative scars, the sustained in
vivo delivery of factors that promote fibrosis and the use of
transgenic animals may lead to new therapeutic options.
MATERIALS AND METHODS
Culture of human cells
Human dermal fibroblasts were derived from neonatal foreskins,
obtained at the Women & Infants Hospital of Rhode Island,
Providence, RI (approved by the Institutional Review Board and in
adherence to the Declaration of Helsinki Principles). Foreskins were
trimmed with scissors to remove excess fatty tissue, rinsed repeatedly
with sterile phosphate buffer solution (PBS), and diced into small
fragments. The fragments were allowed to adhere to the bottom of a
tissue culture plate in a humidified 10% CO2 atmosphere, at 371C
for 1 hour, and were covered with DMEM (Gibco, Grand Island, NY)
supplemented with 20% fetal bovine serum (Hyclone, Logan, UT)
containing 100 U of penicillin and 100mg of streptomycin (Gibco)
per ml. Over a period of 14 days, fibroblasts migrated from the tissue
fragments and formed a confluent layer on the culture plate.
Fibroblasts were harvested with a 0.05% trypsin/EDTA (Gibco)
solution and subcultured in DMEM containing 10% fetal bovine
serum and penicillin/streptomycin.
Retroviral constructs and genetic modification
The retroviral vector, MFG-TGF-b1 was assembled in a two-step
process to remove all 50 and 30 noncoding sequences of the wild-
type human TGF-b1 cDNA. A fragment from the 50 end of TGF-b1
(BglI to BamHI) was isolated, combined with a double-stranded
oligonucleotide (50-CATGCCGCCCTCC-30 and 50-GGGCGG-30) and
ligated as a three-part ligation into purified MFG vector that had
been previously cut with NcoI and BamHI. This intermediate clone,
containing the TGF-b1 50 end, was cut with BamHI, treated with calf
intestinal phosphatase and gel purified. Into this BamHI site was
cloned a PCR product of the remaining 30 end of the TGF-b1 cDNA.
This PCR product, prepared using a forward primer (50-GAAGTGG
ATCCACGAGCCCAAGGGCT-30) and a reverse primer (50-CTG
CTGGATCCAGATCTTCAGCTGCACTTGCAGGAGCG-30) was di-
gested with BamHI and gel purified. A similar strategy was used to
construct an MFG retrovirus encoding a mutant form of TGF-b1 that
is secreted as an active molecule and that does not require activation
(Brunner et al., 1989). In this case, cysteines at positions 223 and
225 were converted to serines. The sequences of the final vectors
encoding either wild-type (latent) TGF-b1 or mutant (active) TGF-b1
were verified by DNA sequencing. Vectors were transfected into a
packaging cell line to generate a stable cell line producing
recombinant retrovirus.
The passage 4 fibroblasts were genetically modified as previously
described (Morgan et al., 1995, Le Doux et al., 2001). Briefly, virus-
producing cells were grown to confluence in a 10 cm dish, the
medium changed (10 ml/plate) and after 24 hours, the medium was
removed, filtered using a 0.45 mm filter, and stored at 801C. For
transduction, 1.15 105 fibroblasts were plated in a 35 mm dish and
incubated overnight. Stocks of recombinant retrovirus were thawed
and brought to 80 mg/ml of chondroitin sulfate C from shark cartilage
(Sigma, St Louis, MO) using a 100 stock. After incubation for
10 minutes at 371C, the virus stock was then brought to 80 mg/ml of
polybrene (hexadimethrine bromide, 1,5-dimethyl-1,5-diazaunde-
camenthylene polymethobromide) (Sigma) using a 100 stock and
incubated for an additional 10 minutes at 371C. The solution was
centrifuged at 10,000 r.p.m. in a 1.5 ml microcentrifuge tube for
5 minutes at room temperature. The visible pellet was resuspended
in cell culture medium to one-tenth of its original volume. The
medium of the human fibroblasts was aspirated and the virus
solution was added and incubated for 24 hours at 371C. The medium
was removed and the cells washed once with fresh culture medium,
and then replaced with new medium. After another 24 hours, the
cells were trypsinized and transferred to 10 cm dishes and grown to
confluence.
Measurement of growth factors levels by ELISA
Control and genetically modified fibroblasts were grown to
confluence in 10 cm dishes and incubated 48 hours in 1% serum
medium. The medium was changed, aliquots harvested at different
time points, and levels of TGF-b1 measured by ELISA (R&D Systems,
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Minneapolis, MN). The antibodies used in the ELISA kit are only able
to detect TGF-b1 in its active form, thus samples are routinely
activated by acidification (HCl) before ELISA. To measure levels of
latent and active TGF-b1, samples were activated according to the
manufacturer’s instructions. To measure levels of TGF-b1 that were
secreted in the active form, the activation step was omitted. After
harvesting the last time point, cells were treated with trypsin,
counted and the values of TGF-b1 were normalized by the volume of
medium in the dish at each time point divided by the final cell
number.
Measurement of cell proliferation
Control and modified cells (3 103 cell/cm2) were plated in six-well
plates (triplicate) in medium containing 10% serum. Cells were
trypsinized and counted in a hematocytometer daily, until reaching
confluence. Cell viability and proliferation were also assessed with
the WST-1 reagent (Roche Diagnostics Corp, Indianapolis, IN)
according to the manufacturer’s recommendations. Cells of each cell
type were plated in a 96-well dish (1 103 per well) in triplicate with
100ml of medium and incubated for 24 hours. Daily up to 7 days,
10 ml of the Wst-1 reagent was added to each well, incubated for
2 hours at 371C and read with an ELISA plate reader at 450 nm. Cells
were followed in culture for up to 3 weeks, and phase contrast
microscopy (Olympus IX70 microscope with a Axio Cam MRc
camera and MRGrab 1.0 Software) (Carl Zeiss Vision GmbH,
Germany) was used to document changes in cell morphology over
time.
Western blot analysis
Control and modified fibroblasts were grown to subconfluence in
60 mm dishes and incubated 48 hours in medium containing 1%
serum. The medium was changed and after 48 hours, cells were
lysed with a buffer containing 1% SDS (Sigma). Protein concentra-
tion was determined by bicinchoninic acid (BCA) assay (Sigma). Cell
extracts were mixed with an equal volume of SDS sample buffer
(125 mM Tris-HCl, pH 6.8, 4% SDS, 20% glycerol, 2% bromophenol
blue, and 5% b-mercaptoethanol) and boiled at 1001C for 5 minutes.
Equal amounts of total protein (5–10mg) were loaded onto 7% SDS-
minigels and separated by PAGE. Separated proteins were trans-
ferred by electrophoresis to a Hybond ECL nitrocellulose membrane
(Amersham Biosciences Corp, Piscataway, NJ) overnight at 41C, in a
buffer containing 25 mM Tris, 192 mM glycine, 20% methanol (vol/
vol). Membranes were treated with blocking buffer (5% nonfat dry
milk, 0.05% Tween 20 in PBS) at room temperature for 2 hours.
Following a brief rinse, membranes were probed with a mouse
monoclonal antibody to SMC a-actin (1:4,000 dilution in blocking
buffer, clone 1A4, Sigma) for 2 hours at room temperature. This was
followed by 3 washes of 5 minutes each in PBST (0.05% Tween 20 in
PBS). Subsequently, membranes were incubated with horseradish
peroxidase-conjugated goat anti-mouse IgG (1:10,000 in blocking
buffer; Chemicon, Temecula, CA) at room temperature for 1 hour.
Following three washes in PBST, the immunoblots were then
incubated with Supersignal West Pico chemiluminescence substrate
(Pierce, Rockford, IL) for 5 minutes and exposed to X-OMAT Kodak
film. The membranes probed for SMA a-actin were stripped with 2%
SDS, 100 mM mercaptoethanol in 62.5 mM Tris-HCl, pH 6.8 for
30 minutes at 701C, and reprobed with a mouse monoclonal
antibody to b-actin (1:5,000 in blocking buffer, clone AC-15,
Sigma), followed by the same procedure. For quantitation, the films
corresponding to each Western blot were photographed using the
Kodak Electrophoresis Documentation and Analysis System 290
(EDAS 290), and analyzed with the Image J Software (National
Institute of Health) obtaining the sum of the pixel values of band
areas. Densitometric analysis results were presented as fold increase.
Measurement of collagen lattice contraction by fibroblasts
Before preparing the gels, 5 ml of BSA (Sigma) solution (0.1% BSA in
PBS, filter sterilized) was pipetted into each well of a six-well plate,
incubated at 371C for 1 hour. 1.4 ml of bovine dermal collagen
Vitrogen (Cohesion, Palo Alto, CA) was mixed with 0.4 ml of 5
DMEM in a 15 ml centrifuge tube cooled on ice. The pH was
adjusted to a range of 7.2–7.5, using a sterile solution of 1 N NaOH.
The control and modified cells were trypsinized from a confluent
tissue culture plate and 0.2 ml of the cell suspension (containing
5 105 cells) was added to the collagen solution, gently mixed and
poured into a well of the six-well plate. Collagen lattices were
allowed to gel for 60 minutes in a 5% CO2 atmosphere at 371C. After
60 minutes, the collagen lattices were detached from the surface of
the well by rimming the lattice with a sterile spatula and gently
swirling the six-well plate. Four milliliters of serum-free medium was
added to each well. Plates were incubated in a 10% CO2
atmosphere at 371C, and the medium changed every 2 days. To
measure contraction, the tissue culture dishes were periodically
placed on top of a transparent metric ruler on an opaque
background, and the diameters of the lattices were recorded as the
average values of the major and minor axes (Pins et al., 2000).
Experiments were repeated 6 times and the values presented with the
standard deviation.
Cell implantation into athymic mice
NCr athymic outbread mice, 5–6-week-old males, were purchased
from Taconic (Germantown, NY), and acclimated for 1 week before
undergoing any procedure. All procedures were approved by the
Brown University Animal Care Committee and carried out in
accordance with the National Institute of Health Guide For The
Care And Use Of Laboratory Animals.
Confluent fibroblasts (modified and unmodified) contained in a
triple flask (500 cm2) were trypsinized, counted and pelleted by
centrifugation. The pellet was resuspended in DMEM and placed in
a 28-gauge 1 ml disposable insulin syringe (Becton-Dickinson,
Frankin Lakes, NJ). Intradermal injection of cells into the dorsal skin
(0.1 ml of DMEM with 1 106 cells) was administered immediately
following cell preparation. Mice were anesthetized using inhalatory
isofluorane (Baxter, Deerfield, IL). Each mouse was injected with
duplicates of control (unmodified cells), cells expressing latent TGF-
b1, cells expressing active TGF-b1, and vehicle alone (DMEM). The
skin was marked with a permanent marker to indicate the injection
sites, which were separated by 1 cm of nontreated skin. A
TegadermTM (3M, St Paul, MN) dressing was applied after injections
to prevent the animal from disturbing the sites. Animals were killed
by CO2 asphyxiation at days 3, 7, 10, 14, 21, and 28. A total of four
batches of animals were used, with two animals for each time point.
All animals survived throughout the experiments.
One injection site was fixed in 10% formalin and embedded in
paraffin for routine histology. The other injection site was
immediately embedded in Tissue-tek OCT compound (Sakura
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Finetek Inc., Torrence, CA) and snap frozen for immunostaining.
There was no tissue response when vehicle without cells was
injected.
Histology and immunostaining
Paraffin-embedded samples were sectioned (5 mm) and stained with
hematoxylin and eosin. For immunostaining, frozen sections (8 mm)
were fixed in cold acetone (201C) for 2 minutes, rinsed in PBS and
incubated in a solution of four parts methanol to one part of 6%
H2O2 (in PBS) for 20 minutes to block endogenous peroxidase
activity. Nonspecific binding sites were blocked for 1 hour in 10%
goat serum (Sigma) and 5% BSA in PBS. Sections were incubated
with a mouse monoclonal anti-vimentin, clone V9 (DakoCytoma-
tion, Carpinteria, CA), diluted 1:50 in the blocking solution for
1 hour at room temperature in a humidified container. Sections were
washed 3 times in PBS, incubated 30 minutes in blocking buffer and
30 minutes with a biotinylated HRP-conjugated secondary antibody
goat anti-mouse (Chemicon) diluted 1:2,500 in blocking buffer.
Sections were developed with 3, 30, 5, 50-tetramethylbenzidine for
10 minutes (Vector, Burlingame, CA). For collagen staining, serial
sections were incubated with a mouse monoclonal anticollagen type
I (Chemicon) diluted 1:20 in blocking buffer overnight at 41C,
incubated with the secondary antibody as above (1:,1000 in
blocking buffer) for 4 hours, and developed with 3, 30-diaminoben-
zidine (Vector). Negative controls were prepared using the same
tissue and were stained with primary antibody alone, secondary
antibody alone and substrate alone. Pictures were taken using an
Olympus IX70 microscope with an Axio Cam MRc camera and
MRGrab 1.0 Software (Carl Zeiss Vision GmbH, Germany).
Statistics
Statistical comparisons between sample groups were made using an
analysis of variance with Pp0.05 indicating a significant difference
between the groups.
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SUPPLEMENTARY MATERIAL
Figure S1. Complex pathway for synthesis, secretion, and activation of
TGF-b1.
Figure S2. Implanted fibroblasts expressing active TGF-b1 form nodules that
persist.
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